| 中文名稱:化合物 NUCC-390 | 英文名稱:NUCC-390 |
| CAS:1060524-97-1 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 98.18% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T001|T12269 |
| 名稱 | NUCC-390 |
| 描述 | NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo. |
| 體外活性 | NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100. NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors. NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1]. NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. |
| 體內(nèi)活性 | NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice[2]. |
| 存儲條件 | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 165 mg/mL (417.15 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (25.28 mM), Suspension. |
| 關(guān)鍵字 | NUCC-390 | NUCC390 | NUCC 390 | CXCR4 |
| 相關(guān)產(chǎn)品 | Soquelitinib | Nicotinamide N-oxide | Plerixafor octahydrochloride | Tanimilast | rac-NBI-74330 | Tannic acid | CXCR2-IN-1 | Kynurenic acid | Artemotil | AZD8309 | CXCL-CXCR1/2-IN-1 | 3-Indoleglyoxylic acid |
| 相關(guān)庫 | 血管生成庫 | 趨化因子抑制劑庫 | 腫瘤免疫治療小分子化合物庫 | 經(jīng)典已知活性庫 | 抗癌化合物庫 | 已知活性化合物庫 | 細胞因子抑制劑庫 | 自噬庫 | 血液病分子庫 | GPCR靶點分子庫 | 免疫/炎癥分子化合物庫 | 膜蛋白靶向化合物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 589.8595萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP2年
|
西安百螢生物科技有限公司
|
2026-05-18 | |
| 詢價 |
VIP5年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2026-06-03 | |
| 詢價 |
VIP1年
|
陜西星貝愛科生物科技有限責(zé)任公司
|
2026-05-24 | |
| 詢價 |
VIP8年
|
成都彼樣生物科技有限公司
|
2026-06-09 |